The Pediatric Brain Tumor Preclinical Testing Program: an update on the current status

2012 ◽  
Vol 224 (06) ◽  
Author(s):  
T Milde ◽  
M Zucknick ◽  
M Kool ◽  
A Korshunov ◽  
H Witt ◽  
...  
2013 ◽  
Vol 225 (06) ◽  
Author(s):  
T Milde ◽  
M Kool ◽  
M Zucknick ◽  
A Korshunov ◽  
H Witt ◽  
...  

2021 ◽  
Vol 12 (1) ◽  
Author(s):  
Yiqun Zhang ◽  
Fengju Chen ◽  
Lawrence A. Donehower ◽  
Michael E. Scheurer ◽  
Chad J. Creighton

AbstractThe global impact of somatic structural variants (SSVs) on gene expression in pediatric brain tumors has not been thoroughly characterised. Here, using whole-genome and RNA sequencing from 854 tumors of more than 30 different types from the Children’s Brain Tumor Tissue Consortium, we report the altered expression of hundreds of genes in association with the presence of nearby SSV breakpoints. SSV-mediated expression changes involve gene fusions, altered cis-regulation, or gene disruption. SSVs considerably extend the numbers of patients with tumors somatically altered for critical pathways, including receptor tyrosine kinases (KRAS, MET, EGFR, NF1), Rb pathway (CDK4), TERT, MYC family (MYC, MYCN, MYB), and HIPPO (NF2). Compared to initial tumors, progressive or recurrent tumors involve a distinct set of SSV-gene associations. High overall SSV burden associates with TP53 mutations, histone H3.3 gene H3F3C mutations, and the transcription of DNA damage response genes. Compared to adult cancers, pediatric brain tumors would involve a different set of genes with SSV-altered cis-regulation. Our comprehensive and pan-histology genomic analyses reveal SSVs to play a major role in shaping the transcriptome of pediatric brain tumors.


2021 ◽  
Vol 37 (3) ◽  
pp. 204-206
Author(s):  
Carolina Nör ◽  
Vijay Ramaswamy

Sign in / Sign up

Export Citation Format

Share Document